More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/Everolimus [159351-69-6]

Everolimus [159351-69-6]

E8419
LKT Laboratories
Estimated Purity≥98%
Product group Chemicals
€ 381,00
25 mg
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    LKT Laboratories
  • Product Name
    Everolimus [159351-69-6]
  • Delivery Days Customer
    7
  • Estimated Purity
    ≥98%
  • Format
    Insoluble in water. Soluble in DMSO (30mg/mL), ethanol (7 mg/mL).
  • Scientific Description
    mTORC1 inhibitor.; Certican, SDZ RAD, 40-O-(2-hydroxyethyl)-rapamycin, RAD001
  • Storage Instruction
    Ambient
  • UNSPSC
    12352200

References

  • Sendur MA, Zengin N, Aksoy S, et al. Everolimus: a new hope for patients with breast cancer. Curr Med Res Opin. 2014 Jan;30(1):75-87. PMID: 24050600. Cai Y, Xia Q, Su Q, et al. mTOR inhibitor RAD001 (everolimus) induces apoptotic, not autophagic cell death, in human nasopharyngeal carcinoma cells. Int J Mol Med. 2013 Apr;31(4):904-12. PMID: 23426850. Hennig M, Bauer D, Wasmuth S, et al. Everolimus improves experimental autoimmune uveoretinitis. Exp Eye Res. 2012 Dec;105:43-52. PMID: 23059401. Ramadan R, Faour D, Awad H, et al. Early treatment with everolimus exerts nephroprotective effect in rats with adriamycin-induced nephrotic syndrome. Nephrol Dial Transplant. 2012 Jun;27(6):2231-41. PMID: 22036940. Wang ZG, Fukazawa T, Nishikawa T, et al. RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer. Oncol Rep. 2010 Apr;23(4):1167-72. PMID: 20204306. Kahan BD, Koch SM. Current immunosuppressant regimens: considerations for critical care. Curr Opin Crit Care. 2001 Aug;7(4):242-50. PMID: 11571421.